Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26962025 | 1.00 | CNR2 (0.36) | CNR2POLBMAPTSRCXIAP | |
| SCHEMBL26961718 | 0.94 | POLB (0.36) | CNR2POLBMAPTSRCXIAP | |
| SCHEMBL29796902 | 0.94 | POLB (0.36) | CNR2POLBMAPTSRCXIAP | |
| SCHEMBL29796919 | 0.93 | POLB (0.36) | CNR2POLBMAPTSRCXIAP | |
| SCHEMBL26962249 | 0.93 | POLB (0.36) | CNR2POLBMAPTSRCXIAP | |
| SCHEMBL26961878 | 0.93 | POLB (0.35) | CNR2POLBMAPTSRCXIAP | |
| SCHEMBL26962062 | 0.93 | POLB (0.35) | CNR2POLBMAPTSRCXIAP | |
| SCHEMBL29796826 | 0.93 | POLB (0.35) | CNR2POLBMAPTSRCXIAP | |
| SCHEMBL26961938 | 0.92 | NPY1R (0.35) | CNR2POLBMAPTSRCXIAP | |
| SCHEMBL29270736 | 0.88 | POLB (0.34) | CNR2POLBMAPTSRCXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022171745-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-18 | — | — | WO | disclosed |